Controversial issues of gout treatment


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Despite the fact that gout is one of the most frequent and well-studied inflammatory diseases of the joints and numerous studies on various issues of diagnosis and treatment are being conducted, there are some questions directly in the treatment of gout on which experts from different countries do not come to a consensus. The accumulation of new information leads to a paradigm shift regarding both urate-lowering and anti-inflammatory therapy for gout, as well as lifestyle correction. The most controversial points are the tactics of prescribing urate-lowering therapy, the choice of the first-line drug, the management and duration of prevention of the development of acute arthritis, the possibility of using colchicine and glucocorticosteroids, IL-1 inhibitors in case of ineffectiveness of non-steroidal anti-inflammatory drugs. In addition, the role of dietary and lifestyle interventions in achieving disease control is discussed.

Texto integral

Acesso é fechado

Sobre autores

M. Chikina

V.A. Nasonova Research Institute of Rheumatology

Email: maria.sorokvasha@yandex.ru

M. Eliseev

V.A. Nasonova Research Institute of Rheumatology

Bibliografia

  1. Kuo C.F., Grainge M.J., Zhang W., et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91.
  2. Pisaniello H.L, Lester S., Gonzalez-Chica D., et al. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthr Res Ther. 2018;20(1):143. Doi: 10.1186/ s13075-018-1633-9.
  3. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020; 79:31-8.
  4. Ревматология: национальное руководство/ Под ред. Е.Л. Насонова, В.А. Насоновой. М., 2008. 379 с.
  5. Araujo F, Cordeiro I., Teixeira F., et al. Portuguese recommendations for the diagnosis and management of gout. Acta Reumatoi Port. 2014;39(2):158-71.
  6. Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015;87(5):10-5. Doi: 10.17116/ terarkh201587510-15. [Eliseev M.S., Barskova V.G., Denisov I.S. Dynamics of clinical manifestations of gout in men (data from a 7-year retrospective observation). Terapevticheskij arkhiv. 2015;87(5):10-5. (In Russ.)].Doi: 10.17116/ terarkh201587510-15.
  7. Dehlin M., Ekstrom E.H., Petzold M., et al. Factors associated with initiation and persistence of urate-lowering therapy. Arthr Res Ther. 2017;19(1):6. doi: 10.1186/s13075-016-1211-y.
  8. Richette P, Doherty M., Pascual E., et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum. Dis. 2017;76(1):29-42. Doi: 10.1136/ annrheumdis-2016-209707.
  9. Taylor T.H., Mecchella J.N., Larson R.J., et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am. J. Med. 2012;125(11):1126-34. doi: 10.1016/j.amjmed.2012.05.025.
  10. Hill E.M., Sky K., Sit M., et al. Doesstarting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 2015;21(3):120-25. doi: 10.1097/RHU.0000000000000235.
  11. FitzGerald J.D., Dalbeth N., Mikuls T., et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthr Rheum. 2020;72(6):879-95. doi: 10.1002/art.41247.
  12. Sarawate C.A., Patel PA., Schumacher H.R., et al. Serum urate levels and gout flares: Analysis from managed care data. J. Clin. Rheumatol. 2006;12(2):61-5.
  13. Elisеev М., Chikina М., Nasonov Е. Prophylaxis of Acute Arthritis at Initiation of Urate-Lowering Therapy in Gout Patients. Recent Advances in Gout. IntechOpen. 2019:57-70. DOI: 10.5772/ intechopen.84456.
  14. Чикина М.Н., Елисеев М.С., Желябина О.В. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103. https:// doi.org/10.14412/1996-7012-2020-2-97-103 [Chikina M.N., Eliseev M.S., Zhelyabina O.V Practical application of national clinical guidelines for the treatment of gout (preliminary data). Sovremennaya revmatologiya. 2020;14(2):97-103. (In Russ.)]. https://doi.org/10.14412/1996-7012-2020-2-97-103
  15. Pascart T., Latourte A., Flipo R.M., et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020;S1297-319X(20)30085-3. doi: 10.1016/j.jbspin.2020.05.002.
  16. Robinson PC., Dalbeth N., Donovan P Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective. Arthr. Care Res. (Hoboken). 2020;10.1002/acr.24357. doi: 10.1002/acr.24357.
  17. Angelidis C., Kotsialou Z., Kossyvakis C., et al. Colchicine Pharmacokinetics and Mechanism of Action. Curr Pharm Des. 2018;24(6):659-63. doi: 10.2174/138161282466618012311004.
  18. Kuncl R.W., Duncan G., Watson D., et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562-8. doi: 10.1056/ NEJM198706183162502.
  19. Kuritzky L., Panchal R. Gout: nonsteroidal antiinflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy. J Pain Palliat Care Pharmacother. 2010;24(4):397-401. doi: 10.3109/15360288.2010.526689.
  20. URL: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=22616d3a-2387-4f6a-9c15-a7aa76be1e1b&t.
  21. URL: https://rheumatolog.su/media/media/ 2018/07/18/clinrec_npvp.pdf
  22. URL: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=143bab73-c9d6-4da9-a447-9ec6109ebaeb&t
  23. Wortmann R.L., Macdonald PA., Hunt B., Jackson R.L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-97. Doi: 10.1016/j. clinthera.2011.01.008.
  24. Khanna D., Khanna PP, Fitzgerald J.D., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthr Care Res. (Hoboken) 2012;64:1447-61. doi: 10.1002/acr.21773.
  25. White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-10. Doi: 10.1056/ NEJMoa1710895.
  26. Choi H., Neogi T., Stamp L., et al. Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert. Arthr Rheum. 2018;70(11):1702-709. doi: 10.1002/art.40583.
  27. Елисеев М.С., Новикова А.М. По следам исследования CARES: сердечно-сосудистая безопасность фебуксостата. РМЖ. 2020;28(7):39-42. [Eliseev M.S., Novikova A.M. In the footsteps of the CARES study: the cardiovascular safety of febuxostat. RMJ. 2020;28(7):39-42. (In Russ.)].
  28. Katsiki N., Borghi C. The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES? Expert Opin Pharmacother. 2018;19(17):1853-56. doi: 10.1080/14656566.2018.1532503.
  29. Becker M.A., Schumacher H.R., Espinoza L.R., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthr Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978.
  30. Chumacher H.R., Becker M.A., Wortmann R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthr. Rheum. 2008;59(11):1540-48. doi: 10.1002/art.24209.
  31. Foody J., Turpin R.S., Tidwell B.A., et al. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. Am Health Drug Benefits. 2017;10(8):393-401.
  32. U.S. Food and Drug Administartion. Safety Alerts for Human Medical Products. URL: https://www. fda.gov/drugs/drugsafety/ucm584702.htm. (дата обращения 13.04.2020).
  33. Liu X., Wang H., Ma R., et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol. 2018;23(3):362-70. doi: 10.1007/s10157-018-1652-5.
  34. Kim S.H., Lee S.Y, Kim J.M., Son C.N. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020;35(4):998-1003. Doi: 10.3904/ kjim.2018.423.
  35. Подагра. Клинические рекомендации Министерства Здравоохранения Российской Федерации. URL: http://cr.rosminzdrav.ru/ff!/ recomend/174.
  36. Schlesinger N., Mysler E., Lin H.Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264-71. doi: 10.1136/ard.2010.144063.
  37. Solomon D., Robert J., et al. Relationship of Interleukin-1Blockade With Incident Gout and Serum Uric Acid Levels. Ann Intern Med. 2018;18:1-8. doi: 10.7326/M18-1167.
  38. Елисеев М.С., Желябина О.В., Мукагова М.В., Насонов Е.Л. Клинический опыт применения блокатора интерлейкина Ιβ канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22. https://doi. org/10.14412/1996-7012-2015-2-16-22
  39. Elisеev M., Sheliabina O. Adherence to uratelowering therapy in patients with severe gout who received сanakinumab following a 5-year retrospective analysis. Ann Rheum Dis. 2020;79(1):445.
  40. Ridker PM., Everett B.M., Thuren T., et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. Doi: 10.1056/ NEJMoa1707914.
  41. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24. doi: 10.1136/ard.2006.055269.
  42. Yu K.H., Chen D.Y, Chen J.H., et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772-87. doi: 10.1111/1756-185X.13266.
  43. Major T.J., Topless R.K., Dalbeth N., Merriman T.R. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018;363:k3951. Doi: 10.1136/ bmj.k3951.
  44. Neogi T., Chen C., Niu J., Chaisson C., et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study Am J Med. 2014;127(4):311-18. Doi: 10.1016/j. amjmed.2013.12.019.
  45. Stamp L.K., O'Donnell J.L., Frampton C., et al. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthr Rheum. 2013;65(6):1636-42. Doi: 10.1002/ art.37925.
  46. Gibson T., Kilbourn K., Horner I., Simmonds H.A. Mechanism and treatment of hypertrigly ceridaemia in gout. Ann Rheum Dis 1979;38:31-5. doi: 10.1136/ard.38.1.31.
  47. Nielsen S.M., Bartels E.M., Henriksen M., et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76(11): 1870-82. doi: 10.1136/annrheumdis-2017-211472.
  48. Nguyen U.D., Zhang Y, Louie-Gao Q., et al. Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy Arthr Care Res. (Hoboken). 2017;69:561-66. doi: 10.1002/acr. 22954.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies